Loading...
Loading...
CRBP| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.4M |
| Gross Profit | -0.4M |
| Operating Expense | 17.3M |
| Operating I/L | -17.3M |
| Other Income/Expense | -0.4M |
| Interest Income | 0.0M |
| Pretax | -17.7M |
| Income Tax Expense | 0.9M |
| Net Income/Loss | -18.7M |
Corbus Pharmaceuticals Holdings, Inc. is a biopharmaceutical company specializing in the development of immune modulators for immuno-oncology and fibrosis diseases. Its lead product, lenabasum, is an oral molecule in Phase II clinical trial for systemic lupus erythematosus. The company also develops anti-integrin monoclonal antibodies for cancer and fibrosis treatment, as well as cannabinoid receptor type 1 inverse agonist program for metabolic disorders and fibrotic diseases. Corbus Pharmaceuticals generates revenue through the development and commercialization of these products, leveraging its licensing agreement with Jenrin Discovery, LLC and its portfolio of patented compounds.
